Peer-reviewed veterinary case report
Does maintenance chemo help dogs with multicentric lymphoma live
By Lautscham, E. M. et al.·Published in Veterinary Record·2017·Small Animal Clinic Hofheim Katharina‐Kemmler‐Str. 7 Hofheim 65719 Germany, Germany·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of a CHOP‐LAsp‐based protocol with and without maintenance for canine multicentric lymphoma
- Species:
- dog
Plain-English summary
A study involving 408 dogs with multicentric lymphoma (a type of cancer) compared two treatment approaches: one that included a maintenance phase after initial therapy and one that did not. The dogs that received the maintenance treatment had a median remission duration of about 216 days and overall survival of 375 days, while those who did not have maintenance had a remission of 184 days and survival of 304 days. Although both treatment methods showed similar outcomes, the study suggests that using a maintenance phase may not significantly improve survival times.
People also search for: dog lymphoma treatment options · canine cancer survival rates · lymphoma maintenance therapy for dogs
Abstract
The recommendation to treat canine lymphoma with a discontinuous protocol is based on small case numbers and mostly historic controls. This study compares duration of first remission (DFR) and overall survival time (ST) with a discontinuous protocol to the same protocol with maintenance phase. 408 dogs were treated with a CHOP‐LAsp (C=cyclophosphamide; H=hydroxydaunorubicin; O=Oncovin; P=prednisolone; LAsp= l ‐asparaginase)‐based 28‐week induction protocol. In 75 dogs (cohort 1), this was followed by a maintenance phase consisting of vincristine, chlorambucil and actinomycin‐D with a total treatment duration of two years. In the subsequent 333 dogs, therapy was discontinued after induction (cohort 2). Median DFR and ST in cohort 1 were 216 and 375 days and 184 and 304 days in cohort 2. 6‐Month, 1‐year and 2‐year survival rates in cohort 1 were 73 per cent, 50 per cent, 24 per cent and 67 per cent, 39 per cent, 21 per cent in cohort 2. There was no significant difference between the two protocols (P=0.291 for ST, P=0.071 for DFR). On multivariate analysis, corticosteroid pretreatment (P=0.005), thrombocytopenia at diagnosis (P=0.019), stage (P=0.009), substage b at relapse (P<0.001), age (P=0.002) and incomplete or unstable remission necessitating intensification of therapy (P=0.004) were negatively correlated with ST in both groups. This study supports the use of a discontinuous protocol for canine multicentric lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1136/vr.104077